Quantum Biopharma Ltd. (QNTM) Form 6-K — May 18, 2026
Quantum BioPharma Ltd. announced that its collaborative imaging study with Massachusetts General Hospital has reached the halfway enrollment mark, accompanied by encouraging preliminary data from the first cohort of participants. The study utilizes a novel PET tracer, [18F]3F4AP, to directly assess demyelinated neurons in multiple sclerosis patients, providing a potential biomarker to track disease progression and treatment response for Quantum’s lead candidate, Lucid-MS.
Key figures
- Royalty cap
- $250 million
- Royalty rate initial
- 7%
- Royalty rate post cap
- 3%
- Ownership stake unbuzzd
- 19.84%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.